Alexion Pharmaceuticals, Inc. Equity-NMS: ALXN

$182.5 0 (November 21, 2024)

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.
Powered by Vested Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Previous close :$182.5

Compare with Other Stocks

Frequently Asked Questions

What is the share price of Alexion Pharmaceuticals, Inc. today?

Alexion Pharmaceuticals, Inc. (ALXN) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Alexion Pharmaceuticals, Inc.?

Yes, Indian Investors can invest in the Alexion Pharmaceuticals, Inc. (ALXN) Share by opening an international trading account with Angel One.

How can I purchase Alexion Pharmaceuticals, Inc. shares in India?

Purchasing Alexion Pharmaceuticals, Inc. (ALXN) share from India can be done by:
  1. Directly: By opening an international trading account with Angel One. The process would include KYC verification.
    The account activation takes a few minutes to a few hours, after which you can start buying Alexion Pharmaceuticals, Inc. (ALXN) by making deposits in US dollars.
  2. Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Alexion Pharmaceuticals, Inc.?

Yes, you can purchase fractional shares of Alexion Pharmaceuticals, Inc. (ALXN) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Alexion Pharmaceuticals, Inc.?

The market capitalization of Alexion Pharmaceuticals, Inc. on January 1, 1970, is $0.

What documents are required to invest in Alexion Pharmaceuticals, Inc. stocks?

In order to invest in Alexion Pharmaceuticals, Inc. (ALXN) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

About Alexion Pharmaceuticals, Inc.

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.